Christoph has a proven record in cancer drug discovery, including contributing to the discovery and development of four FDA-approved medicines and three drugs with breakthrough therapy status. Prior to joining Third Rock, Christoph was chief scientific officer and chief drug hunter at Blueprint Medicines. He joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, he was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research. Christoph contributed to the approval of several novel cancer drugs that now save patients’ lives (Odomzo – Smo inhibitor approved for basal cell carcinoma; Kisqali – CDK4/6 inhibitor approved for HR+/HER2- metastatic breast cancer; Jevtana – cytotoxic approved for hormone refractory metastatic prostate cancer; Zaltrap – VEGF trap approved for metastatic CRC). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. He was involved in the identification of several cancer driver genes including BRAF and PIK3CA. As part of his research, Christoph discovered that all cancers are genetically unstable, which explains the molecular heterogeneity of cancer and why cancers develop resistance to cancer drugs. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature and Science.